Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9977 plus dapagliflozin in heart failure and chronic kidney disease
2020-003126-23Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of balcinrenone and dapagliflozin in heart failure (HF) and chronic kidney disease (CKD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Percent change from baseline in UACR at Week 12. Started Nov 2020; status: completed.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-003126-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003126-23.